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Abstract Objective: We investi-
gated whether preventing
hyperglycemia in septic patients
affected the plasma concentration of
asymmetric-dimethylarginine and if
this was associated with clinical
benefit. Design: A prospective,
multicenter, randomized, controlled,
clinical study. Setting: Intensive
care units (ICU) in three university
hospitals. Patients: A total of 72
patients admitted for severe sepsis or
septic shock, who stayed at least
3 days in the ICU. At admission the
patients were assigned to receive
either tight or conventional glycemic
control. Interventions: Determina-
tion of circulating levels of
asymmetric-dimethylarginine, argi-
nine, interleukin-6, C-reactive-protein
and tumor-necrosis-factor-a. Mea-
surements and results: Blood was
sampled at admission (no differences
between groups), and on the 3rd, 6th,
9th, and 12th (T12) days. Sequential
organ failure assessment was scored
at each sampling time. All the data
were analyzed on an intention-to-treat
basis. The control and treatment
groups received the same energy
intake, glycemia (110.4 ± 17.3 vs.
163.0 ± 28.9 mg/dL, P \ 0.001) and
insulin (P = 0.02) supply differed.
No differences were found in high
plasma levels of asymmetric-
dimethylarginine (P = 0.812) at any
time during the ICU stay. The clinical
course, as indicated by markers of
inflammation, average and maximum
organ failure score, ICU stay and ICU
and 90-day mortality, was the same.
Conclusions: Intensive insulin
treatment, while achieving glucose
control, did not reduce asymmetric-
dimethylarginine in high-risk septic
patients fed with no more than
25 kcal/kg per day to limit ventilatory
demand and to simplify glucose
control. Descriptor: 45 (SIRS/sep-
sis: clinical studies).
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Introduction
Nuclear proteins release asymmetric-dimethylarginine
(ADMA) upon proteolytic degradation during physio-
logical protein turnover. The main metabolic route for
ADMA is decomposition to citrulline and dimethylamine
in a reaction catalyzed by dimethylarginine-dimethyla-
minohydrolase, highly expressed under normal conditions
in the liver, kidney, pancreas and endothelial cells.
ADMA is also eliminated by renal excretion [1–4].
Asymmetric-dimethylarginine competes with arginine
for cationic amino acid transporters of the y+ system [5,
6] and is also an endogenous inhibitor of all the isoforms
of nitric oxide synthase [7].
Oxidative stress and cytokines enhance the activity of
protein arginine methyltransferase, increase methylargi-
nine release due to protein catabolism and variably
influence [8, 9] dimethylarginine-dimethylaminohydro-
lase activity in liver, kidney and pancreas, further
contributing to ADMA plasma levels [8]. In the presence
of high ADMA levels active dimeric isoforms of nitric
oxide synthase may become uncoupled, with the genera-
tion of superoxide anion. ADMA, therefore, is not just a
marker but might also be a mediator of oxidative stress
[10].
High plasma levels of ADMA were recently described
in patho-physiologic states associated with endothelial
dysfunction, oxidative injury, and inflammation, such as
cardiovascular diseases [6, 11, 12], renal diseases [3, 4],
idiopathic pulmonary arterial hypertension [13], and
critical illness [14–16]. ADMA was also a strong pre-
dictor of mortality in critically ill patients [14, 15], in
surgical patients [17], in patients with end-stage renal
disease [18], coronary heart diseases [19, 20], and idio-
pathic pulmonary arterial hypertension [13]. Siroen and
coworkers [15] reported a modulation of ADMA con-
centrations in critically ill surgical patients receiving
insulin for glucose control, and an association between a
low concentration of ADMA and improved survival.
In a multicenter, prospective, randomized, controlled
clinical trial we investigated whether prevention of
hyperglycemia could affect some metabolic pathways
involved in the patho-physiology of sepsis. Here we
report its effects on plasma ADMA concentration.
Materials and methods
Study population
Patients were studied from December 2004 to March
2007 at three university hospitals. The study was
approved by the institutional review boards of each hos-
pital and patients or next-of-kin gave informed written
consent. Patients were enrolled if they met the criteria for
severe sepsis [21]. Exclusion criteria were: (1) age less
than 16 years; (2) hematological malignancies or bone
marrow transplantation; (3) diabetes; (4) dialysis; (5)
likelihood of early death because of the underlying dis-
ease; (6) enrolled patients who were discharged or died
before the third day (second sample for ADMA assay)
were excluded.
Study design
On enrolment, patients were assigned by block randomi-
zation to receive during the ICU stay either tight glycemic
control (treatment group) or conventional glycemic con-
trol (control group). Glucose control and insulin treatment
in the two groups were as described by Van den Berghe
et al. [22]. Briefly, in the treatment group, prompt insulin
was administered whenever blood glucose was higher than
110 mg/dL (6.1 mmol/L) and titrated to maintain glyce-
mia between 80 and 110 mg/dL (4.4 and 6.1 mmol/L). In
the control group, insulin was administered whenever
glycemia exceeded 215 mg/dL (12 mmol/L) and titrated
to keep the levels between 180 and 200 mg/dL (10 and
11 mmol/L). Glycemia was measured every 4 h, or more
frequently when indicated. Parenteral/enteral nutrition
was given, as soon as tolerated, aiming at 25 kcal/kg ideal
body weight during the acute phase of ICU stay.
Data collection
At baseline, the patients’ demographic and clinical char-
acteristics were recorded, including severity of illness,
using the Simplified Acute Physiologic Score II (SAPS II)
[23], and morbidity, using the Sequential Organ Failure
Assessment (SOFA) score [24]. SOFA was also scored at
each sampling time.
Blood sampling for ADMA, arginine, and, as markers
of inflammatory activation, interleukin-6 (IL-6), C-reac-
tive protein (CRP) and tumor necrosis factor-a (TNF-a)
was done immediately after enrolment (T0), and on the
3rd (T3), 6th (T6), 9th (T9) and 12th (T12) days. Circu-
lating levels of ADMA were determined in plasma by
extraction and high-performance liquid chromatography
(HPLC), as previously described [25]. Briefly plasma,
with L-homoarginine added as internal standard, was
applied to a cation-exchange solid phase extraction (SPE)
cartridge (Phenomenex STRATA SCX 100 mg/mL,
Chemtek Analitica, Bologna, Italy), activated beforehand
with methanol and trichloroacetic acid (TCA), 2 mL.
After column washings (TCA 2%, 150 mmol/L phosphate
buffer pH 8.0, methanol), the arginines were eluted with
2% triethylamine in methanol:water (70:30 v/v). The
eluate was dried under nitrogen, redissolved in 0.1 mL
bi-distilled water and derivatized with ortho-phthaldial-
dehyde reagent before analysis. The HPLC was equipped
with a fluorescence detector (k 340 nm, kem 455 nm) and
an Ultrasphere ODS column (250 9 4.6 mm, 5 lm). The
baseline separation of the methylated arginines was
achieved with a gradient between mobile phase A
(sodium citrate buffer, 50 mmol/L, pH 6.2) and B (dis-
tilled water:acetonitrile:methanol; 1:2:2 v/v/v). The levels
found in 77 healthy volunteers (38 males, age
41 ± 16 years, creatinine 0.76 ± 0.13 mg/100 mL) were
ADMA 0.46 ± 0.13, arginine 77.2 ± 31.0 lmol/L.
Statistical analysis
All the data were analyzed on an intention-to-treat basis.
Results are given as mean ± standard deviation (SD)
when normally distributed, or median (interquartile
range) if not. To assess the differences of each variable
over time and between the treatment and control groups,
we built up a general linear mixed model for repeated
measures (GLM) based on every single patient.
Non-normally distributed variables were log-transformed
for the analysis. The model took into account the effect of
treatment (conventional or tight blood glucose control) as
a between-subject factor, and the effect of time as a
within-subject factor. In addition, we used Student’s t test
or Mann–Whitney U test, as needed, to assess differences
between groups, chi-square tests to compare categorical
data, and linear or Spearman’s rank correlation analyses
for the associations of variables. We considered P \ 0.05
statistically significant. Statistical analysis was done using
Stata Statistical Software, release 9.2 (Stata Corporation,
College Station, TX, USA).
Fig. 1 Study flow-chart
Results
During the study, 216 patients were screened; 14 were
excluded for age less than 16 years, 31 for hematological
malignancies/bone marrow transplantation, 21 for diabe-
tes, 15 for any type of artificial renal support and 45 with
likelihood of early death because of the underlying dis-
ease. Finally, 90 were eligible for enrolment (Fig. 1). A
total of 45 patients were randomized to the treatment
group, and 45 to the control group. A total of 36 patients
in both arms had T0 and T3 samples. Table 1 illustrates
the clinical characteristics of the study population and the
baseline profile of biochemical markers. Basal values of
glycemia, CRP, IL-6, TNF-a, ADMA (as such or nor-
malized for creatinine, data not presented), and creatinine
were higher than normal, but did not differ between
groups. Arginine was normal.
Treatment
Half of the patients completed the ICU stay within T12.
With the same overall energy intake, the treatment group
received higher daily dosages of insulin than the control
group. The clear separation over time of daily average
glycemia of patients assigned to tight treatment and
controls is clear from Fig. 2. The percentage of glycemia
samples reaching the target was 43.3% in the treatment
group. The rates of severe hypoglycemia (\40 mg/dL)
was 22.2% (8 patients) in the treatment and 8.3% (3
Table 1 Baseline
characteristics and profile of
biochemical markers of the
study population
Treatment group
(n = 36)
Control group
(n = 36)
P value
Male sex, no. (%) 22 (61.1) 25 (69.4) 0.45
Age (year) 60.3 ± 14.2 64.3 ± 14.3 0.23
IBW (kg) 62.2 ± 8.1 65.1 ± 6.8 0.12
ICU admission type, no. (%)
Medical 24 (72.7) 22 (61.1) 0.56
Surgical unscheduled 8 (24.2) 13 (36.1) 0.56
Surgical scheduled 1 (3.0) 1 (2.7) 0.56
Infection site, no. (%)
Pulmonary 19 (52.7) 16 (44.4) 0.47
Abdominal 8 (22.2) 10 (27.7) 0.58
Urinary tract 5 (13.8) 5 (13.8) 1.00
Others 10 (27.7) 7 (19.4) 0.40
Comorbidities, no. (%)
Hypertension 19 (52.7) 14 (38.8) 0.23
Ischemic heart disease 2 (5.5) 2 (5.5) 1.00
Heart failure 2 (5.7) 1 (2.7) 0.53
Liver failure 3 (8.5) 7 (19.4) 0.18
Diabetes mellitus 7 (19.4) 5 (13.8) 0.52
Chronic obstructive pulmonary disease 8 (22.2) 9 (25.0) 0.78
Chronic renal failure 4 (11.7) 2 (5.5) 0.35
Severe sepsis, no. (%) 6 (16.6) 8 (22.2) 0.55
Septic shock, no. (%) 30 (83.3) 28 (77.7) 0.55
SAPS II score (points) 41.3 ± 14.4 42.2 ± 12.2 0.77
SOFA score (points) 9.3 ± 2.8 8.7 ± 3.3 0.30
SOFA score (organ system [3 points)
Respiratory failure, no (%) 20 (55.6) 23 (63.9) 0.47
Coagulation failure, no (%) 7 (19.4) 4 (11.1) 0.33
Hepatic failure, no (%) 4 (11.1) 2 (5.6) 0.39
Cardiovascular failure, no (%) 26 (72.2) 27 (75.0) 0.79
Neurological failure, no (%) 1 (2.8) 2 (5.6) 0.56
Renal failure, no (%) 7 (19.4) 9 (25.0) 0.57
Creatinine (mg/dL) 2.4 ± 1.8 1.9 ± 1.6 0.24
Blood glucose (mg/dL) 136.7 ± 45.0 151.7 ± 36.6 0.18
CRP (lg/mL) (normal 0.15–6.55) 165.6 (130.3–231.1)* 148.6 (88.9–223.6)* 0.34
IL-6 (pg/mL) (normal 0.19–12.00) 254.5 (62.3–465.8)* 197.6 (61.2–427.0)* 0.88
TNF-a (pg/mL) (normal 3.75–18.25) 33.9 (17.2–74.3)* 42.3 (15.5–99.2)* 0.62
ADMA (lmol/L) (normal 0.33–0.59) 0.86 ± 0.25* 1.05 ± 0.52* 0.06
Arginine (lmol/L) (normal 55.0–95.0) 66.6 ± 34.2 67.3 ± 25.4 0.92
Values are presented as mean ± SD or median (interquartile range) as needed
IBW Ideal body weight; ICU intensive care unit; SAPS II simplified acute physiological score II; SOFA
sepsis-related organ failure assessment; CRP C-reactive protein; IL-6 interleukin-6; TNF-a tumor
necrosis factor-a; ADMA asymmetric dimethylarginine
*P \ 0.001 vs. normal value
patients) in the control group (P = 0.189). No neurological
consequences were observed (Table 2).
Asymmetric-dimethylarginine level increased over
time in treatment group (GLM within group: P = 0.012),
but, during the sample period, ADMA levels were not
different between groups (GLM between groups:
P = 0.812) (Fig. 2). The same was true for values cor-
rected for creatinine level (P = 0.439) and for arginine
(P = 0.692). No difference was found between groups for
CRP, IL-6, TNF-a, transfusions, incidence of septic
shock, daily and maximum SOFA, ICU stay, and ICU and
90-day mortality.
Daily ADMA concentration at the 6th day was asso-
ciated with ICU stay (Spearman’s rank correlation
coefficient r = 0.52, P = 0.036) in control group, while
in treatment group an association was found with SOFA
score at the 9th day (r = 0.53, P = 0.015).
Discussion
During the last few years, the relation between ADMA
plasma levels and adverse effects has been frequently
described [3, 4, 6, 9, 11–20]. Elevation of ADMA, like
other methylated aminoacids [26], quite likely results
from increased protein breakdown, possibly coupled with
impairment of the degrading enzyme in liver, kidney or
endothelium [8], and/or renal failure.
The possibility that ADMA not only indicates risk, but
actually contributes to adverse events interfering with the
Fig. 2 Time course of recorded
average daily blood glucose
(general linear mixed model
between groups: P \ 0.001).
Asymmetric-dimethylarginine
levels increase with time
(general linear mixed model
within group: P = 0.012) in
treatment group, but do not
differ between groups
(P = 0.812). Data are
expressed as mean ± SD. The
dotted line represents the upper
limit of blood glucose level for
the treatment group, shaded
area represent the normal range
(up to the 95th percentile) for
asymmetric-dimethylarginine
nitric oxide fine tuning of the microcirculation involving
the endothelium, platelets and white blood cells [5–7, 9]
could open new therapeutic perspectives. Attempts to
lower the plasma ADMA concentration have not been
encouraging [17]; however, in surgical intensive care
patients, Siroen et al. [15] have suggested that ADMA
levels could be modulated by insulin-mediated normo-
glycemia and this partly explained clinical beneficial
effects, reduced morbidity, and mortality associated with
insulin treatment.
The assumptions of the normoglycemia/insulin
hypothesis in inflammatory conditions are as follows [9]:
a catabolic status results in cellular ADMA spillover and
high plasma levels, while hyperglycemia increases
expression of the cationic amino acid transport system y+
[9, 27, 28] and inhibits the activity of dimethylarginine-
hydrolase [29]. In this scenario, insulin reduces protein
catabolism [26], affects the cationic amino acid y+
transport system and may thereby increase the uptake of
ADMA in organs able to eliminate it [27, 28, 30, 31].
Insulin may also preserve dimethylarginine-hydrolase
inhibition due to hyperglycemia [29]. All these data work
in favor of a compensatory ADMA metabolism with
ADMA disappearing from plasma with insulin treatment
able to achieve glycemic control.
We set out to test the interesting hypothesis of meta-
bolic control of ADMA in the first 12 days of ICU stay in
the most stressed critically ill patients, i.e. those admitted
with severe sepsis and septic shock [20]. Patients were
really at high-risk: about 50% had pneumonia, 25%
peritonitis, and about 80% were admitted in septic shock.
Their severity at admission, the elevated levels of the
inflammatory markers CRP, IL-6, TNF-a, and the number
and degree of organ failures during the ICU stay (our
patients had a mean daily SOFA score of 7 and a worst
score of 10 out of a maximum of 14 points), resulted in a
substantial mortality rate and quite long ICU stays
(Table 2). As expected, mean basal ADMA plasma level
was high, higher than levels reported in less critically ill
patients [14, 15, 17] and fitted with those reported in the
only study on septic patients [16].
Despite the significant differences in glycemia and
insulin supply between the treatment and control groups,
we were unable to find differences in plasma levels of
ADMA during the first 12 days ICU stay, as well as
differences in the overall clinical course of sepsis as
indicated by markers of inflammation, mean and maxi-
mum SOFA score, ICU stay, and (but the study was not
powered enough) for ICU/90-day mortality.
Searching for a possible explanation, we analyzed the
differences between our and Siroen’s study [15]: the
number of patients was similar (79 for Siroen and 72 in
our study), all Siroen’s patients had undergone thoracic
surgery whereas in our case-mix only 33% were surgical
patients (abdominal and thoracic); Siroen et al. did not
report the incidence of severe sepsis, all our patients had
severe sepsis and 88% of them had septic shock during
ICU stay. Noteworthy, according to a more severe stress
reaction, our basal ADMA levels were consistently higher
than Siroen et al. Moreover, to limit ventilatory demand
[32] and simplify glycemic control during the acute phase
of illness, we supplied less energy than Siroen et al. (he
reports about 1,700 kcal/day). Despite this, glucose con-
trol was less optimal than that reported by Siroen et al.
Both these factors could have reduced the anabolic effect
of the treatment. However, even in this scenario, our data
Table 2 Biochemical markers
and clinical characteristics
during care
Variable Treatment group
(n = 36)
Control group
(n = 36)
P value
T3–T12 days
Creatinine (mg/dL) 1.8 ± 2.4 1.5 ± 1.2 0.09
Blood glucose (mg/dL) 110.4 ± 17.3 163.0 ± 28.9 \0.0001
CRP (lg/mL) 74.3 (34.6–136.8)* 77.0 (29.6–121.4)* 0.48
IL-6 (pg/mL) 56.0 (28.4–167.7)* 47.6 (21.9–146.7)* 0.18
TNF-a (pg/mL) 21.6 (14.3–34.7) 19.0 (15.0–32.7) 0.84
Arginine (lmol/L) 78.8 ± 33.2 81.3 ± 30.8 0.56
Insulin (UI/day) 74.5 ± 141.1 38.8 ± 44.8 0.02
kcal/kg/day 20.3 ± 16.3 18.9 ± 2.7 0.74
Whole ICU stay
Red cell transfusion, no (%) 21 (58.3) 24 (66.6) 0.53
Daily SOFA score (points) 7.4 ± 3.6 6.7 ± 3.5 0.08
Maximum SOFA score (points) 10.4 ± 2.6 10.0 ± 3.1 0.22
Septic shock, no (%) 31 (86.1) 32 (88.9) 0.55
Length of stay (days) 16 [8.1–28.5] 13 [6.5–23.5] 0.74
ICU mortality, no (%) 8 (22.2) 6 (16.7) 0.55
90-day mortality, no (%) 13 (36.1) 11 (30.6) 0.62
Values are presented as mean ± SD or median (interquartile range) as needed
CRP C-reactive protein; IL-6 interleukin-6; TNF-a tumor necrosis factor-a; ICU intensive care unit;
SOFA sepsis-related organ failure assessment
*P \ 0.001 vs. normal values
confirm ADMA as a marker of stress/severity; its levels at
the peak of stress were significantly related with organ
failure score, and ICU stay.
Asymmetric-dimethylarginine plasma level in severe
sepsis/septic shock is massively increased due to systemic
inflammatory response and organ failure. At least during
the first 12 days of ICU stay, intensive insulin treatment
was unable to reduce ADMA levels as reported (15).
Differences in composition (sepsis incidence), severity of
the case-mix, very high ADMA levels, hypo-caloric
energy supply, and not easy glucose control, might par-
tially explain the finding. However, the cost/benefit ratio
of a more aggressive energy supply (and of insulin to
ensure normoglycemia) in the early care of such critically
ill patients needs to be carefully evaluated in the light of
the risks in critically ill patients, and particularly in the
septic ones, as we ourselves observed and as reported in a
wider case-mix by Glucocontrol and VISEP studies [33,
34].
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